ATLAS fair value
CA$6.13
Above fair value · 95% premium
Curaleaf stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Toronto Stock Exchange · Canada
Prices as of Oct 27, 2026 · CAD
CA$6.13
Above fair value · 95% premium
47%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Curaleaf's fair value at about CA$6.13 per share (reasonable range: CA$4.65 to CA$8.07). At CA$11.95, the stock trades 95% above it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Curaleaf a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CA$10.42 and CA$13.30; in 9 out of 10, between CA$8.39 and CA$16.52. Estimated annual volatility is 60%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Curaleaf sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks CURA.TO has traded between CA$2.59 and CA$16.92. Today it is 29.4% below that high and 361% above its low.
Its beta is 1.60: it tends to move more than the market, both up and down.
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities.
Want to see everything about Curaleaf?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About CA$6.13 per share according to ATLAS (reasonable range: CA$4.65 to CA$8.07). With the stock at CA$11.95, it is 95% above it.
47%: close to a coin flip. In half of the simulated outcomes, CURA.TO ends the month between CA$10.42 and CA$13.30.
Curaleaf's market capitalization is CA$3.2B. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 60%. In a typical month, half of the outcomes end between CA$10.42 and CA$13.30.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy